S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)
S&P 500   5,258.04 (+0.18%)
DOW   39,823.15 (+0.16%)
QQQ   444.94 (+0.02%)
AAPL   172.11 (-0.69%)
MSFT   421.38 (-0.01%)
META   488.49 (-1.09%)
GOOGL   151.13 (+0.17%)
AMZN   180.58 (+0.42%)
TSLA   175.50 (-2.41%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   180.16 (+0.32%)
BABA   72.39 (+1.12%)
T   17.67 (+0.68%)
F   13.25 (+1.45%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   175.94 (-2.32%)
DIS   122.48 (+1.24%)
AMC   3.73 (-14.06%)
PFE   27.84 (+0.22%)
PYPL   66.99 (+0.63%)
XOM   116.31 (+1.17%)

Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

$120.93
+0.42 (+0.35%)
(As of 03:46 PM ET)
Today's Range
$120.03
$121.53
50-Day Range
$115.19
$132.77
52-Week Range
$111.25
$147.98
Volume
188,217 shs
Average Volume
625,399 shs
Market Capitalization
$7.62 billion
P/E Ratio
19.76
Dividend Yield
N/A
Price Target
$195.08

Jazz Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
60.6% Upside
$195.08 Price Target
Short Interest
Bearish
4.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.41mentions of Jazz Pharmaceuticals in the last 14 days
Based on 23 Articles This Week
Insider Trading
Acquiring Shares
$1.44 M Bought Last Quarter
Proj. Earnings Growth
15.17%
From $16.15 to $18.60 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.97 out of 5 stars

Medical Sector

11th out of 938 stocks

Pharmaceutical Preparations Industry

5th out of 433 stocks

JAZZ stock logo

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

JAZZ Stock Price History

JAZZ Stock News Headlines

Jazz Pharmaceuticals: Cancer and the Combination Approach
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Cancer and the Combination Approach
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals
JAZZ Apr 2024 110.000 put
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
Employees
2,800
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$195.08
High Stock Price Target
$230.00
Low Stock Price Target
$131.00
Potential Upside/Downside
+61.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$414.83 million
Pretax Margin
7.77%

Debt

Sales & Book Value

Annual Sales
$3.83 billion
Cash Flow
$28.54 per share
Book Value
$59.36 per share

Miscellaneous

Free Float
60,228,000
Market Cap
$7.62 billion
Optionable
Optionable
Beta
0.59

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

JAZZ Stock Analysis - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" JAZZ shares.
View JAZZ analyst ratings
or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price target for 2024?

13 Wall Street analysts have issued 12 month price targets for Jazz Pharmaceuticals' shares. Their JAZZ share price targets range from $131.00 to $230.00. On average, they expect the company's share price to reach $195.08 in the next twelve months. This suggests a possible upside of 60.6% from the stock's current price.
View analysts price targets for JAZZ
or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2024?

Jazz Pharmaceuticals' stock was trading at $123.00 at the start of the year. Since then, JAZZ stock has decreased by 1.3% and is now trading at $121.44.
View the best growth stocks for 2024 here
.

Are investors shorting Jazz Pharmaceuticals?

Jazz Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,770,000 shares, an increase of 15.9% from the February 29th total of 2,390,000 shares. Based on an average daily volume of 637,100 shares, the short-interest ratio is presently 4.3 days. Approximately 4.6% of the company's stock are short sold.
View Jazz Pharmaceuticals' Short Interest
.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our JAZZ earnings forecast
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its earnings results on Wednesday, February, 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by $0.04. The specialty pharmaceutical company earned $1.01 billion during the quarter, compared to analysts' expectations of $1.01 billion. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 31.27% and a net margin of 10.82%.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of 18.150-19.350 for the period, compared to the consensus estimate of 19.940. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.11%), Vanguard Group Inc. (10.10%), LSV Asset Management (3.72%), Wellington Management Group LLP (2.05%), Polaris Capital Management LLC (2.01%) and Pacer Advisors Inc. (1.63%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Philip L Johnson, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce.
View institutional ownership trends
.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
This page (NASDAQ:JAZZ) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners